This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Alnylam And Collaborators Publish Novel Method For Detection Of Tissue-Specific, RNAi-Mediated Gene Silencing

Stocks in this article: ALNY

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the publication of a new paper describing a novel technique called circulating Extracellular RNA Detection (cERD). The paper, titled “ Tissue-specific gene silencing monitored in circulating RNA” (Sehgal et al., RNA, doi:10.1261/rna.042507.113) appears online as an Advance Article in the journal RNA. The cERD method enables the quantification of circulating messenger RNA (mRNA) and micro-RNA (miRNA) as a way of monitoring tissue-specific RNA silencing. It also enables confirmation of an RNAi-mediated mechanism of action using a PCR-based technique. The cERD method could have broad applicability in clinical studies since it allows for monitoring of tissue-specific mRNA levels using a non-invasive technique.

“Detection of target gene knockdown is typically made possible by measurement and quantification of mRNA levels in tissue samples and, if the target protein is secreted, corresponding protein levels in serum or plasma. Further, establishing proof of mechanism for RNAi therapeutics involves analysis of RNAi-mediated target mRNA cleavage with a PCR-based technique in tissue samples. However, the utility of these techniques is limited, since many proteins do not enter circulation, and the need to collect biopsies creates a significant challenge to the routine monitoring of mRNA expression levels or the RNAi mechanism of action in tissues,” said Rachel Meyers, Ph.D., Vice President of Research and RNAi Lead Development at Alnylam. “These new published data establish the applicability of the cERD method in multiple species, including rats and non-human primates, and thus the general utility of measuring circulating serum mRNA to confirm RNAi-mediated tissue gene silencing. Specifically, we have shown that changes in circulating RNA levels correspond closely to changes in tissue RNA levels, suggesting that RNA levels from biological fluids provide an accurate ‘real-time’ representation of tissue RNA status. These findings are important to the development of RNAi therapeutics, as the cERD method could be extended to the clinical setting to allow the routine, accurate, and frequent measurement of organ-specific target gene knockdown and/or RNAi mechanism without the need for tissue biopsies.”

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs